A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Completed · Phase 2

Conditions studied: Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease

In brief

This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in children \<12 months of age with Alagille Syndrome \[ALGS\] or Progressive Familial Intrahepatic Cholestasis \[PFIC\].

Key facts

Study ID
NCT04729751
Run by
Mirum Pharmaceuticals, Inc.
People needed
27
Starts
2021-09-09
Expected to finish
2024-12-17
Last updated by the study team
2026-06-02

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.